Author archives

Dan-Corneliu JINGA

Latest posts by Dan-Corneliu JINGA (see all)

Articles signed on MÆDICA, JCM:

Histology of Male Breast Lesions. Series of Cases and Literature Review

SELECT ISSUE


MÆDICA - a Journal of Clinical Medicine | Vol. 13, nr. 3, 2018
CNCSIS - CMR - B+ OBBCSSR

Members Area


Histology of Male Breast Lesions. Series of Cases and Literature Review

, , , , , , and

ABSTRACT

Background: Breast carcinoma is the most important cause of death in women’s oncologic pathology worldwide. Due to its high frequency, important advances in diagnostic and management of this entity were made. Because of its rarity (only 0.5-1% in all breast cancers), little is known about male breast cancer, and no specific male standardised protocol was made, treatment and follow-up being adopted from women breast cancer guidelines. We consider that this entity, with its hormone specific profile, is worth being considered for further studies, taking into account that male breast cancer has a far worse prognostic than female breast cancer.
Methods: We present our four-year experience with male breast lesions in a retrospective review study, including gynecomastia and breast carcinoma cases.
Results: We identified 17 male breast lesions, 11 of them with a diagnosis of gynaecomastia, the rest being breast carcinomas. Four malignant lesions were encountered in the 5th, 6th and 7th decade, with two of them in young adults (35 and 40 years old). In a single case, two different histotypes of breast carcinoma were found. All of them were G2, with tumoral stages varying between IB to IV. Androgen receptors were expressed in each case, in different percentages.
Conclusions: Male breast carcinoma is a rare entity with a poor prognosis, a diffuse and profound invasion of adjacent structures, and a high expression of hormone receptors, and with no histologic relation to gynaecomastia, considering that no associated benign lesions were found.
Keywords: gynaecomastia, male breast carcinoma, androgen receptors, hormonal profile.

Full text | PDF

Breast Cancer Immunotherapy

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 10, nr. 2, 2015

CNCSIS - CMR - B+ OBBCSSR

HIGHLIGHTS

What is plagiarism

Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Breast Cancer Immunotherapy

, and

ABSTRACT

Although unlikely to replace current standard of care therapies, immunotherapy is emerging as a critical component of breast cancer treatment. Despite initial setbacks, clinical benefit is now evident through immunomodulation and cancer vaccines. Over the past decade, passive immunotherapeutic strategies such as anti-HER2 monoclonal antibody (mAb) therapy have significantly improved the prognosis in HER2 overexpressing breast cancers. Novel active immunotherapeutic strategies include checkpoint blockade modifiers, also a mAb therapy. Although non-specific, checkpoint blockade modifiers show great promise in clinical trials. A form of active and specific immunotherapy, cancer vaccines may be used alone or in conjunction with these aforementioned mAb therapies. While there is significant initial promise, the complexities of the host immune system-tumor interaction and the vast array of potential immune targets require the field of cancer immunotherapy to be further developed. Here, we briefly discuss the field of breast immunotherapy to date and its implications for the future of breast cancer care.

Full text | PDF

The Tomorrow’s Personalized Medicine – The Killer of Today’s Statistical Medicine

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 9, nr. 2, 2014

CNCSIS - CMR - B+ OBBCSSR

The Role of Ankle-Brachial Index for Predicting Peripheral Arterial Disease

and

Today we practice statistical medicine: what else is treating patients according to the evidence based medicine data? The best diagnosis and treatment guidelines are based on the positive statistical results of clinical trials.

But what about the 10-20-40% patients in each study who did not respond appropriately to the therapy? Can we recognize them today before starting the statistically approved therapy, which will work only on the 90-80-60% statistically correct patients?

We do not recognize them yet. But soon we will do and will treat them differently from those who respond statistically normally

Full text | PDF